TRVI

Trevi Therapeutics Inc

TRVI, USA

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

https://www.trevitherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TRVI
stock
TRVI

Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com Investing.com Nigeria

Read more →
TRVI
stock
TRVI

Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$21

Analyst Picks

Strong Buy

7

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

9.76

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-6.22 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.92 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.05

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 80.14% of the total shares of Trevi Therapeutics Inc

1.

NEA Management Company, LLC

(10.8578%)

since

2025/06/30

2.

Rubric Capital Management LP

(7.0061%)

since

2025/06/30

3.

BlackRock Inc

(6.7377%)

since

2025/06/30

4.

Vanguard Group Inc

(4.3659%)

since

2025/06/30

5.

Vivo Capital, LLC

(3.6853%)

since

2025/06/30

6.

AllianceBernstein L.P.

(3.5157%)

since

2025/06/30

7.

Woodline Partners LP

(3.3228%)

since

2025/06/30

8.

Siren, L.L.C.

(3.2344%)

since

2025/06/30

9.

Octagon Capital Advisors LP

(3.0154%)

since

2025/06/30

10.

MPM Oncology Impact Management LP

(2.7977%)

since

2025/06/30

11.

Orbimed Advisors, LLC

(2.7168%)

since

2025/06/30

12.

Vanguard Total Stock Mkt Idx Inv

(2.5644%)

since

2025/07/31

13.

Affinity Asset Advisors, LLC

(2.0809%)

since

2025/06/30

14.

Marshall Wace Asset Management Ltd

(2.0348%)

since

2025/06/30

15.

Balyasny Asset Management LLC

(1.9334%)

since

2025/06/30

16.

Fidelity Select Biotechnology

(1.7726%)

since

2025/07/31

17.

AB Small Cap Growth A

(1.7158%)

since

2025/07/31

18.

iShares Russell 2000 ETF

(1.5059%)

since

2025/08/31

19.

State Street Corp

(1.5051%)

since

2025/06/30

20.

Geode Capital Management, LLC

(1.4673%)

since

2025/06/30

21.

Point72 Asset Management, L.P.

(1.4195%)

since

2025/06/30

22.

Viking Global Investors LP

(1.2671%)

since

2025/06/30

23.

Eventide Asset Management, LLC

(1.1343%)

since

2025/06/30

24.

Eventide Healthcare & Life Sciences I

(1.1343%)

since

2025/06/30

25.

Citadel Advisors Llc

(1.0833%)

since

2025/06/30

26.

BlackRock Advantage Small Cap Core Instl

(0.6938%)

since

2025/07/31

27.

Vanguard Institutional Extnd Mkt Idx Tr

(0.652%)

since

2025/07/31

28.

Fidelity Small Cap Index

(0.6253%)

since

2025/06/30

29.

iShares Russell 2000 Growth ETF

(0.5427%)

since

2025/08/31

30.

Wellington Global Hlthcr Eq USD G Ac

(0.5096%)

since

2025/07/31

31.

Principal SmallCap Growth I Instl

(0.4222%)

since

2025/07/31

32.

AB US Small Cap Growth Collective Tr W

(0.4161%)

since

2025/07/31

33.

Biotech Growth Ord

(0.404%)

since

2025/05/31

34.

MEDICAL BioHealth EUR Acc

(0.3405%)

since

2025/06/30

35.

iShares Biotechnology ETF

(0.3404%)

since

2025/08/31

36.

Fidelity Extended Market Index

(0.3274%)

since

2025/07/31

37.

Vanguard Russell 2000 ETF

(0.2963%)

since

2025/07/31

38.

AB Small Cap Core Z

(0.2352%)

since

2025/07/31

39.

SPDR® S&P Pharmaceuticals ETF

(0.2331%)

since

2025/08/31

40.

Invesco Dorsey Wright Healthcare MomtETF

(0.2245%)

since

2025/08/29

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.08

EPS Estimate

-0.1

EPS Difference

0.02

Surprise Percent

20%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.